

## The effect of saffron, *Crocus sativus* stigma, extract and its constituents, safranal and crocin on sexual behaviors in normal male rats

H. Hosseinzadeh<sup>a,\*</sup>, T. Ziaee<sup>b</sup>, A. Sadeghi<sup>b</sup>

<sup>a</sup>Pharmacology and Toxicology Department, Pharmaceutical Research Center, Faculty of Pharmacy, Mashhad University of Medical Sciences, P.O. Box 1365-91775, Mashhad, IR Iran

<sup>b</sup>Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IR Iran

### Abstract

In this study, the aphrodisiac activities of *Crocus sativus* stigma aqueous extract and its constituents, safranal and crocin, were evaluated in male rats. The aqueous extract (80, 160 and 320 mg/kg body wt.), crocin (100, 200 and 400 mg/kg body wt.), safranal (0.1, 0.2 and 0.4 ml/kg), sildenafil (60 mg/kg body wt., as a positive control) and saline were administered intraperitoneally to male rats. Mounting frequency (MF), intromission frequency (IF), erection frequency (EF), mount latency (ML), intromission latency (IL) and ejaculation latency (EL) were the factors evaluated during the sexual behavior study. Crocin, at all doses, and the extract, especially at doses 160 and 320 mg/kg body wt., increased MF, IF and EF behaviors and reduced EL, IL and ML parameters. Safranal did not show aphrodisiac effects. The present study reveals an aphrodisiac activity of saffron aqueous extract and its constituent crocin.

© 2007 Elsevier GmbH. All rights reserved.

**Keywords:** Saffron; *Crocus sativus*; Crocin; Safranal; Sildenafil; Aphrodisiac activity; Sexual activity

### Introduction

Sexual dysfunction is a serious medical and social symptom that occurs in 10–52% of men and 25–63% of women. Of men aged 40–70 years, an estimated 34.8% have moderate to complete erectile dysfunction (Porst, 2004). It has been recently estimated that more than 152 million men worldwide experienced erectile dysfunction (ED) in 1995, and that this number will rise by 170 million, to approximately 322 million by the year 2025 (Kandeel et al., 2001). Treatment of ED usually involves the psychotherapeutic approach. Pharmacotherapy in-

volves locally acting vasoactive drugs such as papaverin and alprostadil (Bostandjiev and Mitra, 2004), and first-line oral therapy for ED includes phosphodiesterase type 5 (PDE-5) inhibitors such as sildenafil, vardenafil, and tadalafil, which inhibit hydrolysis of the second messenger cyclic guanosine monophosphate (cGMP), whose production is promoted by nitric oxide (NO) release within the penile smooth cells (Montorsi et al., 2006; Wespes et al., 2006). Central stimulants like apomorphine (Heaton, 2000; Montorsi et al., 2003) and herbal drugs with aphrodisiac activity are also involved in treatment of ED. Surgical interventions are also used, including insertion of penile prostheses (Bostandjiev and Mitra, 2004). The available drugs and treatments have limited efficacy, unpleasant side-effects such as headache, flushing, dyspepsia, nasal congestion and color visual disturbances with PDE-5

\*Corresponding author. Fax: +98 511 8823251.  
E-mail addresses: [hosseinzadehh@mums.ac.ir](mailto:hosseinzadehh@mums.ac.ir),  
[hosseinzadehh@yahoo.com](mailto:hosseinzadehh@yahoo.com), [hosseinzadehh@gmail.com](mailto:hosseinzadehh@gmail.com)  
(H. Hosseinzadeh).

inhibitors (Porst, 2004; Dhawan et al., 2003; Tharakan and Manyam, 2005) as well as contraindications in certain disease conditions. A variety of botanicals such as *Tribulus terrestris*, *Aframomum melegueta*, *Eurycoma longifolia*, *Cnidium monnieri*, *Ferula harmonis*, *Mucuna pruriens*, *Lepidium meyenii* and yohimbine as an alkaloid obtained from the bark of *Pausinystalia johimbe* (*Corynanthe johimbe*) (Tharakan and Manyam, 2005), as well as *Passiflora incarnate* (Dhawan et al., 2003) are reported to have a potential effect on the sexual functions, supporting older claims and offering new hope (Tharakan and Manyam, 2005).

*Crocus sativus* L., commonly known as saffron, is a perennial stemless herb of the Iridaceae family that is widely cultivated in Iran and other countries, including India and Greece (Ríos et al., 1996). Commercial saffron comprises the dried red stigma with a small portion of the yellowish stamina attached. Compounds considered pharmacologically active and important are volatile agents (e.g., safranal), bitter principles (e.g., picrocrocin) and dye materials (e.g., crocetin and its glycoside, crocin) (Ríos et al., 1996). In modern pharmacological studies, saffron or its active constituents have demonstrated anticonvulsant (Hosseinzadeh and Khosravan, 2002), antidepressant (Hosseinzadeh et al., 2004), anti-inflammatory and antinociceptive (Hosseinzadeh and Younesi, 2002) and antitumor activities (Abdullaev, 1993; Escribano et al., 1996). Radical scavenger effects as well as learning and memory-improving properties (Zhang et al., 1994; Abe et al., 1999) and promotion of the diffusion of oxygen in different tissues have also been reported (Ríos et al., 1996). Saffron extract is also chemopreventive and showed protective effects on genotoxin-induced oxidative stress in Swiss albino mice (Abdullaev et al., 2002; Nair et al., 1995; Premkumar et al., 2003). In traditional medicine, saffron is recommended as aphrodisiac agent (Madan et al., 1966). Thus, in this study the effects of saffron stigma extract and two active constituents, crocin and safranal, on sexual behaviors were evaluated in male rats.

## Materials and methods

### Animals

Virgin Wistar rats weighing  $230 \pm 10$  g each were obtained from a random bred colony in the animal house of Mashhad University of Medical Sciences. Animals were housed in the colony room under a 12/12 h light/dark cycle at  $21 \pm 2$  °C. Animals had free access to water and food. All animal experiments were carried out in accordance with Mashhad University of Medical Sciences, Ethical Committee Acts.

### Plant material

*Crocus sativus* L. stigmata were collected from Ghaen (Khorasan province, Northeast of Iran). A voucher specimen was authenticated and deposited in the Herbarium of Faculty of Pharmacy, Mashhad University of Medical Sciences.

### Quantification of crocin and safranal in saffron aqueous extract

To quantify crocin and safranal in an aqueous saffron extract, a modified method was used (Sujata et al., 1992; Hadizadeh et al., 2007). The extract of authentic stigmata was passed through a 0.2- $\mu$ m Millipore filter (Millipore, Bedford, MA, USA) and eluted with 100% methanol. This quantification was carried out by Shimadzu HPLC LC-10ADvp system integrated with a Shimadzu SCL-10Avp system controller and a SPD-10Avp UV-visible spectrophotometric on a reversed-phase Shim-pak C18, VP-ODS analytical column (25 cm  $\times$  4.6 mm I.D. with a  $12.0 \pm 1.0$  nm pore size and  $4.6 \pm 0.3$   $\mu$ m particle size), using an isocratic mobile phase of acetonitrile:water (76:24) at a flow rate of 1.2 ml/min. A Rheodyne Shimadzu Model 7725i injector was used to inject 25  $\mu$ l of the sample from a 25  $\mu$ l Hamilton straight-edge needle syringe onto the column. All data were recorded and analyzed on a chromatography workstation using Shimadzu Class-VP<sup>TM</sup> 6.10 software (Hadizadeh et al., 2007).

### Chemicals

Crocine and safranal were purchased from Fluka. Sildenafil was obtained from Poursina, IR Iran.

### Preparation of extracts

40 g of stigma powder were macerated in 1500 ml water for 72 h. The mixture of plant and water was subsequently centrifuged (5 min, 3000 rpm) and the supernatants were evaporated to dryness under reduced pressure at 40 °C. The yield of the extract was 45% (w/w).

### Treatment

Male rats were divided into 11 groups of 6 each. All agents were administered intraperitoneally. Rats of group I received 10 ml/kg body wt. normal saline as vehicle and served as negative control. Group II rats received sildenafil citrate at a dose of 60 mg/kg body wt. and served as the reference group. Rats from groups III, IV and V received saffron extracts at doses of 80, 160 and 320 mg/kg body wt., respectively. Rats from groups

VI, VII and VIII received crocin at doses of 100, 200 and 400 mg/kg body wt. Rats from groups IX, X and XI received safranal at doses of 0.1, 0.2 and 0.4 ml/kg body wt. The primed female was then introduced into the chamber after 2 h injection of agents to male rats and the following sexual behavior parameters were recorded:

The following parameters of the copulatory behavior were recorded: (I) mount latency (ML): time taken for the first mount following the introduction of females; (II) intromission latency (IL): time taken for first intromission following introduction of the female; (III) ejaculation latency (EL): time interval between first intromission and first ejaculation; (IV) mount frequency (MF): no. of mounts observed in 30 min; (V) intromission frequency (IF): no. of intromission observed in 30 min; (VI) erections frequency (EF): no. of erections observed in 30 min (Gopumadhavan et al., 2003; Ramachandran et al., 2004).

### Statistical analysis

Data are expressed as mean  $\pm$  s.e.m. Statistical analysis was performed using one-way ANOVA followed by Tukey–Kramer *post-hoc* test for multiple comparisons. The *p*-values less than 0.05 were considered to be statistically significant.


### Results

Using the calibration curve, the quantities of crocin and safranal in a sample of *C. sativus* extracts were about 19.7 and 0.25 mg/g, respectively. The yields produced by purifying Fluka crocin and safranal on the spectrophotometric system were about 41% and 75%, respectively.


The aqueous extract increased MF (160 and 320 mg/kg body wt.), IF (320 mg/kg body wt.) and EF (160 and 320 mg/kg body wt.) significantly (Figs. 1–3). Sildenafil also changed these parameters. At all doses (80, 160 and 320 mg/kg body wt.), the extract decreased ML, IL and EL significantly (Figs. 4–6). Crocin (100, 200 and 400 mg/kg body wt.) also increased MF, IF and EF (except a dose of 100 mg/kg body wt.) significantly (Figs. 1–3). This constituent of saffron decreased ML, IL and EL significantly (10–12). At all doses (0.1–0.4 ml/kg body wt.), safranal showed no stimulatory effects on sexual behavior activities (Figs. 4–6). Safranal at higher doses of 0.2–0.4 ml/kg body wt. showed a sedative effect.

### Discussion

The present study provides evidence for the ability of the crude extract of saffron stigmata and its constituent,




**Fig. 1.** Effect of *Crocus sativus* stigma aqueous extract and its constituents crocin and safranal on mount latency in normal male rats. Values presented as the mean  $\pm$  s.e.m.;  $n \geq 6$ . \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  as compared to saline (Tukey's test).




**Fig. 2.** Effect of *Crocus sativus* stigma aqueous extract and its constituents crocin and safranal on intromission frequency in normal male rats. Values presented as the mean  $\pm$  s.e.m.;  $n \geq 6$ . \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  as compared to saline (Tukey's test).

crocin, to act as aphrodisiac agents. Safranal, on the other hand, did not facilitate several aspects of copulatory behaviors. Safranal did not increase, but actually decreased these activities.

Crocetin, a constituent of saffron, significantly restored the EDR (endothelium-dependent relaxation) of the thoracic aorta in hypercholesterolemic rabbit, which might be explained by its action to increase the vessel eNOS activity, leading to elevation of NO production. Crocetin increased serum level of nitric oxide (NO) (Tang et al., 2006). As crocin (the crocetin digentiobiosyl-ester) converts to crocetin, it is possible that this component acts in a way similar to PDE-5 inhibitors such as sildenafil. Crocin is soluble in water; thus the aqueous extract of saffron may act partially via crocin component.




**Fig. 3.** Effect of *Crocus sativus* stigma aqueous extract and its constituents crocin and safranal on erection frequency in normal male rats. Values presented as the mean + s.e.m.;  $n \geq 6$ . \*\* $p < 0.01$ , \*\*\* $p < 0.001$  as compared to saline (Tukey's test).




**Fig. 4.** Effect of *Crocus sativus* stigma aqueous extract and its constituents crocin and safranal on mount frequency in normal male rats. Values presented as the mean + s.e.m.;  $n \geq 6$ . \* $p < 0.05$ , \*\*\* $p < 0.001$  as compared to saline (Tukey's test).

Crocin concentration-dependently inhibited the  $[Ca^{2+}]_i$  elevation induced by  $H_2O_2$  in cultured bovine aortic smooth muscle cells. Crocin could inhibit the extracellular  $Ca^{2+}$  influx and release of intracellular  $Ca^{2+}$  stores in the endoplasmic reticulum (He et al., 2004). Reduction of intracellular  $Ca(2+)$  release may contribute to relaxation of the corpus cavernosum, leading to erection (Williams et al., 2005).

Safranal showed affinity to bind benzodiazepine receptors (Hosseinzadeh and Sadeghnia, 2007). This effect may be involved in the sedative activity of this component and its reduction of sexual activity. In a behavioral study, safranal exhibited antidepressant activity and, as it increased swimming time in the modified forced swimming test, it was concluded that it might inhibit the reuptake of



**Fig. 5.** Effect of *Crocus sativus* stigma aqueous extract and its constituents crocin and safranal on intromission latency in normal male rats. Values presented as the mean + s.e.m.;  $n \geq 6$ . \*\*\* $p < 0.001$  as compared to saline (Tukey's test).



**Fig. 6.** Effect of *Crocus sativus* stigma aqueous extract and its constituents crocin and safranal on ejaculation latency in normal male rats. Values presented as the mean + s.e.m.;  $n \geq 6$ . \*\* $p < 0.01$ , \*\*\* $p < 0.001$  as compared to saline (Tukey's test).

serotonin (Hosseinzadeh et al., 2004). Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are clearly associated with delayed ejaculation, inability to ejaculate and absent or delayed orgasm (Lane, 1997).

We found that the extract contains 19.7 mg/g of crocin. It seems this amount of carotenoid has a minor role in the aphrodisiac properties of saffron. A synergistic action of many constituents including crocins, crocetin, dimethyl crocetin, flavonoids, sugars, vitamins, amino acids and minerals may be involved in this activity. At the moment, the high cost of saffron may be an obstacle to use of this plant to treat sexual dysfunction. However, this study may help to find new agents to treat these disorders.

In summary, the present study provides evidence that the aqueous crude extract of *C. sativus* and crocin can be considered to have aphrodisiac properties.

## Acknowledgment

We are grateful to Dr. Farzin Hadizadeh, Assistant Professor of Medicinal Chemistry, Mashhad, Iran, as he provided valuable information used to quantify the constituents of saffron extract.

## References

- Abdullaev, F.J., 1993. Biological effects of saffron. *Biofactors* 4, 83–86.
- Abdullaev, J., Caballero-Ortega, H., Riveron-Nigrete, L., Pereda-Miranda, R., Rivera-Luna, R., Hernandez, M.J., Perez-Lopez, I., Espinosa-Aguirre, J.J., 2002. In vitro evaluation of chemopreventive potential of saffron. *Rev. Invest. Clin.* 54, 430–436.
- Abe, K., Sugiura, M., Ymaguchi, S., Shoyama, Y., Saito, H., 1999. Saffron extract prevents acetaldehyde-induced inhibition of long-term potentiation in the rat dentate gyrus in vivo. *Brain Res.* 851, 287–289.
- Bostandjiev, R., Mitra, S.K., 2004. Clinical evaluation of *Tentex forte* and Himcolin cream in the treatment of functional erectile dysfunction. *Med. Update* 11, 47–51.
- Dhawan, K., Kumar, S., Sharma, A., 2003. Aphrodisiac Activity of methanol extract of leaves of *Passiflora incarnate* Linn. in mice. *Phytother. Res.* 17, 401–403.
- Escribano, J., Alonso, G.L., Coca-Prados, M., Fernandez, J.A., 1996. Crocin, safranal and picrocrocin from saffron (*Crocus sativus* L.) inhibit the growth of human cancer cells in vitro. *Cancer Lett.* 100, 23–30.
- Gopumadhavan, S., Rafiq, M., Venkataranganna, M.V., Kulkarni, K.S., Mitra, S.K., 2003. Assessment of 'Tentex royal' for sexual activity in an experimental model. *Indian J. Clin. Pract.* 13, 23–26.
- Hadizadeh, F., Mahdavi, M., Emami, S.A., Seifi, M., Nassirli, N., Khashayarmanesh, H., Hassanzadeh, M., Asili, J., Shariatmoghadam, A., Noorbakhsh, R., 2007. Evaluation of ISO method in saffron qualification. In: Proceedings of the second international symposium on saffron biology and technology. *Acta Hort.* 739, 405–410.
- He, S.Y., Qian, Z.Y., Tang, F.T., 2004. Effect of crocin on intracellular calcium concentration in cultured bovine aortic smooth muscle cells. *Yao Xue Xue Bao* 39, 778–781.
- Heaton, J.P.W., 2000. Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. *Neurosci. Biobehav. Rev.* 24, 561–569.
- Hosseinzadeh, H., Khosravan, V., 2002. Anticonvulsant effects of aqueous and ethanolic extracts of *Crocus sativus* L. stigmas in mice. *Arch. Iran. Med.* 5, 44–47.
- Hosseinzadeh, H., Sadeghnia, H.R., 2007. Protective effect of safranal on pentylenetetrazol-induced seizures in the rat: involvement of GABAergic and opioids systems. *Phytomedicine* 14, 256–262.
- Hosseinzadeh, H., Younesi, H.M., 2002. Antinociceptive and anti-inflammatory effects of *Crocus sativus* L. stigma and petal extracts in mice. *BMC Pharmacol.* 2, 7.
- Hosseinzadeh, H., Karimi, Gh., Niapoor, M., 2004. Anti-depressant effects of *Crocus sativus* stigma extracts and its constituents, crocin and safranal, in mice. *Acta Hort.* 650, 435–445.
- Kandeel, F.R., Vivien, K.T., Koussa, V.K.T., Swerdloff, R.S., 2001. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. *Endocrinol. Rev.* 22, 342–388.
- Lane, R.M., 1997. Critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. *J. Psychopharmacol.* 11, 72–82.
- Madan, C.L., Kapur, B.M., Gupta, U.S., 1966. Saffron. *Econ. Bot.* 20, 377.
- Montorsi, F., Peranib, D., Anchisib, D., Salonia, A., Scifob, P., Rigiolic, P., Dehoa, F., De Vitod, M.L., Heatone, J., Rigattia, P., Faziob, F., 2003. Brain activation patterns during video sexual stimulation following the administration of apomorphine: results of a placebo-controlled study. *Eur. Urol.* 43, 405–411.
- Montorsi, F., Briganti, A., Salonia, A., Rigatti, P., Burnett, A.L., 2006. Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? *Eur. Urol.* 49, 979–986.
- Nair, S.C., Kurumboor, S.K., Hasegawa, J.H., 1995. Saffron chemoprevention in biology and medicine: a review. *Cancer Biother.* 10, 257–264.
- Porst, H., 2004. Phosphodiesterase type-5 inhibitors: a critical comparative analysis. *EAU Update Ser.* 2, 56–63.
- Premkumar, K., Abraham, S.K., Santhiya, S.T., Ramesh, A., 2003. Protective effects of saffron (*Crocus sativus* L.) on genotoxins-induced oxidative stress in Swiss albino mice. *Phytother. Res.* 17, 614–617.
- Ramachandran, S., Sridhar, Y., Sam, S.K., Saravanan, M., Leonard, J.T., Anbalagan, N., Sridhar, S.K., 2004. Aphrodisiac activity of *Butea frondosa* Koen. ex Roxb. extract in male rats. *Phytomedicine* 11, 165–168.
- Rios, J.L., Recio, M.C., Giner, R.M., Máñez, S., 1996. An update review of saffron and its active constituents. *Phytother. Res.* 10, 189–193.
- Sujata, V., Ravishankar, G.A., Venkataraman, L.V., 1992. Methods for the analysis of the saffron metabolites crocin, crocetins, picrocrocin and safranal for the determination of the quality of the spice using thin-layer chromatography, high-performance liquid chromatography and gas chromatography. *J. Chromatogr.* 624, 497–502.
- Tang, F.T., Qian, Z.Y., Liu, P.Q., Zheng, S.G., He, S.Y., Bao, L.P., Huang, H.Q., 2006. Crocetin improves endothelium-dependent relaxation of thoracic aorta in hypercholesterolemic rabbit by increasing eNOS activity. *Biochem. Pharmacol.* 72, 558–565.
- Tharakan, B., Manyam, B.V., 2005. Botanical therapies in sexual dysfunction. *Phytother. Res.* 19, 457–463.
- Wespes, E., Amar, E., Hatzichristou, D., Hatzimouratidis, K., Montorsi, F., Pryor, J., Vardi, Y., 2006. Guidelines on erectile dysfunction: an update. *Eur. Urol.* 49, 806–815.
- Williams, B.A., Liu, C., Deyoung, L., Brock, G.B., Sims, S.M., 2005. Regulation of intracellular Ca<sup>2+</sup> release in corpus cavernosum smooth muscle: synergism between nitric oxide and cGMP. *Am. J. Physiol. Cell Physiol.* 288, C650–C658.
- Zhang, Y.X., Sugiura, M., Saito, H., Shoyama, Y., 1994. Acute effects of *Crocus sativus* L. on passive avoidance performance in mice. *Biol. Pharmacol. Bull.* 17, 217–221.